Paying for Recovery: Contingency Management, Stimulant Use Disorder, & Survival w/Dr. Park

Beyond SSRIs: Psilocybin in Treatment-Resistant Depression & What It Means for Substance Use Disorders

Can psilocybin help patients with treatment-resistant depression and what does the latest clinical evidence mean for people dealing with both depression and addiction? In this episode of The Transformed Minds (Host Rx), psychiatrist Dr. O breaks down a landmark 2022 NEJM phase II randomized, double-blind, multicenter trial examining psilocybin therapy for treatment-resistant depression (TRD). Dr. O explains what qualifies as TRD, walks through the trial's three-arm dosing design (1 mg, 10 mg, and 25 mg plus structured psychological support), and interprets the primary outcome, MADRS score change at three weeks. The 25 mg dose showed statistically significant and clinically meaningful improvement, but the story gets more complex by week 12. This episode is especially valuable for clinicians, patients, and advocates navigating dual diagnosis care co-occurring depression and substance use disorders. Dr. O covers: - psilocybin-assisted therapy- treatment-resistant depression, - MADRS depression scale, - psychedelic safety- mental health equity- substance use disorder and depression Whether you're a mental health professional, someone living with TRD, or simply following the rapidly evolving conversation around psychedelic medicine, this episode gives you the evidence-based framework to think critically, not just hopefully about what psilocybin can and cannot do right now.

From Craving to Cognitive Flexibility: Psychedelic-Assisted Treatment for Alcohol Use

Can psilocybin-assisted psychotherapy help reduce heavy drinking in alcohol use disorder? In this Host Rx episode, Dr. O analyzes the landmark 2022 JAMA Psychiatry randomized clinical trial examining psilocybin combined with psychotherapy for adults with alcohol dependence. Dr. O explains: • The study design and outcomes • How psilocybin may promote cognitive flexibility • Safety considerations • Ethical and policy challenges • What this means for the future of addiction treatment This episode also explores implementation barriers, reimbursement issues, disparities in access, and the importance of rigorous scientific oversight as psychedelic medicine evolves. Educational only, not medical advice. #Psilocybin #AlcoholUseDisorder #PsychedelicTherapy #AddictionPsychiatry #MentalHealthPodcast

Paying for Recovery: Contingency Management, Stimulant Use Disorder, & Survival w/Dr. Park

Stimulant overdose deaths are rising rapidly and one of the most effective treatments remains widely misunderstood. In this episode of Transform Minds Podcast, Dr. O sits down with addiction psychiatrist Dr. Dong Chan Park to explore contingency management (CM), an evidence-based treatment for stimulant use disorder that uses immediate rewards to reinforce recovery behaviors. Drawing on a 2025 American Journal of Psychiatry cohort study, this conversation examines how contingency management may significantly reduce all-cause mortality while addressing the ethical, clinical, and policy barriers limiting broader adoption. WHAT YOU’LL LEARN: * Why stimulant-involved overdose deaths continue to rise * How contingency management works in real-world addiction treatment * Why CM is often criticized as “bribery” * The evidence linking CM to lower mortality * Trauma-informed approaches to stimulant treatment * The role of ADHD, housing instability, and relapse triggers in recovery * How CBT, IOP, and multidisciplinary care support long-term outcomes FEATURED ARTICLES & RESOURCES: * Coughlin LN et al. Contingency Management for Stimulant Use Disorder and Association With Mortality. Am J Psychiatry. 2025. https://doi.org/10.1176/appi.ajp.20250053 [https://doi.org/10.1176/appi.ajp.20250053] * National Academies of Sciences: Medications and Behavioral Treatments for Substance Use Disorders * SAMHSA: Treatment of Stimulant Use Disorders Recovery is possible. Evidence-based treatment saves lives. #ContingencyManagement #StimulantUseDisorder #AddictionPsychiatry #MentalHealthPodcast #AddictionRecovery

Youth Self-Harm, Substance Use, and Suicide Risk: What the Data Actually Show | Epi 6

In this episode, Dr. O examines how self-harm, substance use, and emotional dysregulation interact to increase risk in adolescents and young adults. Drawing on the Global Burden of Disease Study 2025, this discussion highlights how mental disorders, substance use, and self-harm are leading contributors to disability in ages 10–24. Key topics include: * Substance use as a major risk factor for suicidal thoughts and behaviors * Emotional dysregulation and impulsivity * Social media and behavioral risk patterns * Clinical implications for screening and early intervention Featured research includes: * Xu et al., Translational Psychiatry 2025 * Jones et al., Substance Abuse 2023 * López-Martínez et al., Behavioral Sciences 2025 RESOURCES:If you or someone you know is in immediate danger, call emergency services (911 in the U.S.) right away. *U.S.: Call or text 988 (Suicide and Crisis Lifeline) OR Chat via 988lifeline.org *International: Visit findahelpline.com to find local resourcesYou are not alone. Help is available.

When Policy Lags Behind Science: Buprenorphine Dosing Reconsidered with Dr. Drits | Ep 5

Are dose caps on buprenorphine costing lives? In this episode of the Transform Mind Podcast, Dr. O and Dr. Drits dig into the evidence and the gaps around buprenorphine dosing for opioid use disorder In the fentanyl era, drawing on a 2023 narrative review by Grande and colleagues published in the Journal of Addiction Medicine. Higher doses are consistently linked to better treatment retention. Yet dose caps persist in clinical practice and insurance policy, even as the opioid supply has fundamentally shifted. Dr. O and Dr. Drits break down why, and what clinicians and patients can do about it.In this episode: → Why the "ceiling effect" applies to respiratory depression not to craving or withdrawal relief → What the evidence says about retention, fentanyl, and dosing → How to advocate for patients within institutional and insurance constraints → Common myths about diversion and high-dose buprenorphine → Shared decision-making in practice Learning Objectives By the end of this episode, listeners will be able to: 1. Describe the evidence base regarding buprenorphine dose limits and clinical outcomes. 2. Explain how buprenorphine pharmacology informs safety at higher doses. 3. Identify policy and systemic factors that influence dosing practices. Apply evidence-based reasoning to clinical and systems-level decision-making in opioid use disorder care. Chapters: 00:00 High Dose Benefits 01:23 Podcast Intro Format 02:34 Why Dose Caps Matter 07:48 Guest Perspective Policy Lag 11:27 Dose Limits Today 14:44 Buprenorphine Pharmacology 18:07 Retention Saves Lives 20:31 Fentanyl Needs Higher Doses 22:25 Advocacy Under Limits 24:53 Training And Myths 28:38 Case Dosing Decisions 34:38 Shared Decision Making 37:34 Ceiling Effect Explained 39:24 Key Takeaways Reference: Grande LA et al. "High-dose buprenorphine for the treatment of opioid use disorder in the context of fentanyl exposure." Journal of Addiction Medicine, 2023. ⚠️ This podcast is for educational purposes only and does not constitute medical advice. Clinical decisions should be made in consultation with a qualified healthcare provider. #BuprenorphineTreatment #OpioidUseDisorder #MOUD #FentanylCrisis #AddictionMedicine #HarmReduction #TransformMindPodcast